Enhanced bioavailability of nano-sized chitosan–atorvastatin conjugate after oral administration to rats
- 16 August 2011
- journal article
- Published by Elsevier BV in European Journal of Pharmaceutical Sciences
- Vol. 44 (3), 241-249
- https://doi.org/10.1016/j.ejps.2011.08.001
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS processInternational Journal of Pharmaceutics, 2008
- Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) processEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Synthesis, Analysis, in Vitro Characterization, and in Vivo Disposition of a Lamivudine–Dextran Conjugate for Selective Antiviral Delivery to the LiverBioconjugate Chemistry, 2007
- Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisationEuropean Journal of Pharmaceutics and Biopharmaceutics, 2006
- The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugsInternational Journal of Pharmaceutics, 2004
- Nanosuspensions of poorly soluble drugs — reproducibility of small scale productionInternational Journal of Pharmaceutics, 2000
- New insights into the pharmacodynamic and pharmacokinetic properties of statinsPharmacology & Therapeutics, 1999
- Coupling of the antiviral agent zidovudine to polyaspartamide and in vitro drug release studiesJournal of Controlled Release, 1998
- Characteristics and Significance of the Amorphous State in Pharmaceutical SystemsJournal of Pharmaceutical Sciences, 1997
- Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjectsCancer Cell, 1996